As Biohaven CEO Coric preps FDA filing for new migraine spray, he's already scouting for celebrity spokesperson – Endpoints News

Days after reporting positive Phase III results for intranasal migraine med zavegepant, Biohaven chairman and CEO Vlad Coric is talking about marketing plans. It’s a month or more before Biohaven will file for FDA approval and likely a year before launch, but Coric is already thinking about messaging and commercialization.
His plan? A dual strategy to attract potential patients around speed to relief – zavegepant study results show the spray can provide relief in as fast as 15 minutes and a return to normal in 30 minutes – along with a secondary anti-nausea benefit in using an intranasal versus a pill.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Back in January 2019, the late House Oversight Committee chair Elijah Cummings kicked off a nearly 3-year-long drug pricing investigation that culminated today in a major new report detailing how prices for vital drugs have risen substantially since their launch, while calling on the Senate to pass a bill that will allow Medicare to negotiate some prices.
The committee’s investigation focused on 12 of the most expensive drugs for Medicare, showing massive price spikes that have accumulated over the years and made some drugs, like insulin, entirely unaffordable for some, to the point where some diabetics have had to ration their life-saving insulin, and some have died.
While the ultimate fate of Novartis’ big generics arm Sandoz may still be up in the air, there’s no doubt it’s in play as a potential buyout target.
Overnight, Reuters picked up on a report out of Germany that EQT and the billionaire Strüngmann brothers — enjoying a huge windfall from the overnight success of BioNTech’s mRNA Covid vaccine — are kicking the tires at Sandoz. And Novartis CEO Vas Narasimhan confirmed they’ve seen some M&A interest, even if no hard offers are on the table.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
KEY POINTS
Patients prefer oral dosing, but swallowing tablets can be a challenge for many patients.
The Zydis® orally disintegrating tablet (ODT) platform addresses challenges associated with oral dosing, expanding benefits for patients and options for healthcare providers.
A strong growth trajectory is expected for ODTs given therapeutic innovation and continued technology development.
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing or sucking, offer a patient-friendly dosage form for the administration of small-molecule drugs, peptides and proteins. With the potential for multiple sites of drug absorption, often faster onset action for the active pharmaceutical ingredient (API), and potentially greater bioavailability, ODTs are an attractive option for drug developers considering first-to-market formulations or product line extensions of existing drugs with compatible API. In this report, we look at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.
Please signup to continue — it’s fast and free. This article is sponsored by Catalent and produced by Endpoints Studio.
Bristol Myers Squibb brought in more than $9 billion in sales from its anticoagulant Eliquis in 2020, and it continues to see growth with more than $8 billion in sales in the first nine months of 2021 (and another nearly $4.5 billion for Pfizer in 2021).
But in 2022, one of the largest PBMs in the US, CVS Caremark, has recently decided to no longer cover the megablockbuster, and instead will only offer coverage for warfarin and Janssen’s Xarelto.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
The new J&J has a fresh corporate face to show the public — several in fact.
As the healthcare conglomerate follows a now familiar pharma path in separating itself into an innovation-focused R&D-based group from its less appealing consumer side, it’s promoting some key individuals to the executive committee that steers the company.
Those fresh faces include Mathai Mammen, the global head of R&D who joins the inner circle as executive vice president of pharmaceuticals, R&D. External innovation chief Bill Hait becomes executive vice president, chief external innovation, medical safety and global public health officer. Jim Swanson, until today simply the chief information officer, adds the EVP part to his title in moving onto the committee. And Vanessa Broadhurst, company group chairman, global commercial strategy organization, has been appointed EVP, global corporate affairs.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Each year, we aim to highlight 20 extraordinary women who are leaving their mark on drug R&D — and this year’s group was no exception.
Our list, while by no means exhaustive, includes scientists, CEOs, researchers and professors who are supercharging the discovery and development of new therapies worldwide. Our team of writers spent time with each honoree (with a few exceptions), learning their stories and sketching profiles, which you’ll find in our special report.
For the second time, we brought the celebration to a live virtual audience, featuring an award presentation followed by a panel on what it takes to break the glass ceiling in biopharma with Kojin Therapeutics CEO Luba Greenwood, AskBio CEO Sheila Mikhail, and Silverback Therapeutics CEO Laura Shawver. Our panelists had a lively discussion on how the industry’s culture has changed, how to handle sexual harassment, the progress we’ve made and the challenges that still hold women back today.
We applaud each of our honorees for scaling the heights of biopharma R&D. You got to meet most of them via brief recordings we played during our live event. Below, you’ll find bonus videos offering a longer glimpse into those interviews. And if you didn’t get a chance to tune in to our main event live, you can replay the entire show.
Unlock this article along with other benefits by subscribing to one of our paid plans.
Eli Lilly will license in Regor Therapeutics therapies for metabolic disorders, as a part of an agreement announced Friday that will give the Chinese biotech an upfront payment of up to $50 million, part of which is an equity investment.
In a vaguely worded release, Lilly said it has a license for certain Regor “intellectual property” and will have an option to extend that license. In exchange, Lilly will oversee global clinical development and commercialization for any therapies, with the exception of China, Macau, Hong Kong and Taiwan. Regor, a Shanghai-based company, will reserve the rights to these regions.
Roche’s Genentech got a leg up in the packed anti-TIGIT race earlier this year when the FDA granted it the first breakthrough designation in the field based on some upbeat mid-stage data in non-small cell lung cancer. Now, looking to keep its lead, the pharma giant is offering a two-and-a-half-year look at the same patient group — but will two deaths crush its chances?
A combination of Genentech’s anti-TIGIT cancer tiragolumab plus PD-L1 inhibitor Tecentriq reduced patients’ risk of disease progression or death by 38% compared to those who received Tecentriq alone at a median follow-up of 2.5 years, the company said on Friday. In a pre-specified exploratory analysis of participants with high levels of PD-L1, the combo reduced the risk of disease worsening or death by 71% compared to the Tecentriq group.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Myelodysplastic syndrome is not only hard to say, it’s also hard to explain. So Novartis hired Noma Bar, an artist and illustrator well-known for his simple and striking imagery to create a video that explains the rare blood cancer.
The 2-minute video uses bold colors and seamless graphics that morph from image to image. A white blood cell, for instance, turns into a Pacman-like character gobbling infection, while a drop of blood turns into a dial pointer and then an exclamation point.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2021
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWSby John Carroll & team — all the news at 11:30am ET
EARLY EDITIONby Arsalan Arif — news and links at 7:15am ET
ENDPOINTS MANUFACTURINGWeekly biopharma manufacturing report, Thursdays at 2pm ET
ENDPOINTS WEEKLYRecaps the most important developments on Saturday 6am ET
ENDPOINTS FDA+Regulatory news and analysis for drug developers, Wednesday 2pm ET
ENDPOINTS MARKETING RXCovers advertising and the multibillion-dollar drug commercialization world, Tuesday 2pm ET
Join over 125,300 biopharma colleagues who rely on Endpoints News every business day for the latest developments in drug discovery, development, and commercialization.
ENDPOINTS NEWSdaily at 12 PM ET sample issue
EARLY EDITIONdaily at 7:15 AM ET sample issue
ENDPOINTS WEEKLYSaturday at 6 AM ET
ENDPOINTS MANUFACTURING Thursday at 2 PM ET sample issue
ENDPOINTS FDA+ Wednesday at 2 PM ET sample issue
ENDPOINTS MARKETING RX Tuesday at 2 PM ET sample issue

source


0Shares

Add a Comment

Your email address will not be published. Required fields are marked *